therapeutic action: analgesia

Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic pain

mycolabadmin

Researchers found that psilocybin, the active ingredient in magic mushrooms, significantly reduced chronic pain in mice through activation of specific serotonin receptors. The effects lasted for up to two weeks after a single dose, suggesting lasting changes in how the nervous system processes pain. This study suggests psilocybin could be a promising new treatment for chronic pain conditions like neuropathy and inflammation.

Read More »

Isolation, identification and antibacterial activity of endophytes from the seeds of Panax japonicus

mycolabadmin

This study investigated microscopic organisms living inside Panax japonicus seeds to understand why these seeds are difficult to grow. Researchers found the best way to clean the seeds and identified ten different microorganism species living in them. Most of these were fungi that may actually prevent seed germination, while certain bacteria species appear beneficial for plant growth and could potentially be used to improve seed cultivation in the future.

Read More »

Isolation, identification and antibacterial activity of endophytes from the seeds of Panax japonicus

mycolabadmin

Researchers isolated and identified 10 different microorganisms (7 fungi and 3 bacteria) living inside Panax japonicus seeds. They found that a specific type of bacteria (Enterobacteriaceae and Pseudomonas) may help promote seed growth, while certain fungi may inhibit it. The study also determined the best way to sterilize seeds before experimentation, which is important for studying plant propagation of this valuable medicinal herb.

Read More »

Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial

mycolabadmin

Researchers surveyed chronic pain patients about their willingness to participate in a trial testing psilocybin (a compound from magic mushrooms) as a pain treatment. About 77% of patients were interested in participating. Interestingly, patients who had previously used psychedelics were much more willing to join the trial. Common reasons for wanting to participate included needing new pain treatments, while concerns about side effects and practical difficulties like attending multiple appointments discouraged others.

Read More »
Scroll to Top